근위축성측색경화증(ALS) 시장 : 규모, 점유율, 동향 분석, 기회, 예측(2019-2030년)

Global Amayotrophic Lateral Sclerosis (ALS) Market Size to Expand at Significant CAGR to Surpass USD 1.45 Billion by 2030

Global Amayotrophic Lateral Sclerosis (ALS) Market is thriving due to rising ALS prevalence, increased awareness, advancements in therapeutic options, and government funding in enhancing research and development efforts for more effective treatments.

BlueWeave Consulting, a leading strategic consulting, and Market research firm, in its recent study, estimated Global Amayotrophic Lateral Sclerosis (ALS) Market size by value at USD 902 million in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global Amayotrophic Lateral Sclerosis (ALS) Market size to expand at a CAGR of 7.10% reaching a value of USD 1,456 million in 2030. Global Amyotrophic Lateral Sclerosis (ALS) Market is driven by increasing incidence rates, advancements in medical research, and rising awareness about ALS. Enhanced diagnostic techniques and growing investment in biotechnology for ALS treatment contribute significantly. Additionally, governments' support and initiatives for rare disease research, along with collaborations between pharmaceutical companies and research institutions, propel market growth. The development of novel therapies and increasing clinical trials for ALS treatments further boost the growth of Global Amayotrophic Lateral Sclerosis (ALS) Market.

Opportunity - R&D initiatives for novel therapies

The growth of Global Amyotrophic Lateral Sclerosis (ALS) Market is significantly driven by increased research and development initiatives aimed at discovering novel therapies. Pharmaceutical companies and research institutions are investing heavily in R&D to develop innovative treatments, such as gene therapies, stem cell therapies, and novel drug candidates. These advancements are expected to improve patient outcomes and provide more effective treatment options, fueling market growth and offering hope for better management of ALS.

Impact of Escalating Geopolitical Tensions on Global Amayotrophic Lateral Sclerosis (ALS) Market

Escalating geopolitical tensions can significantly impact the Global Amyotrophic Lateral Sclerosis (ALS) Market. Disruptions in international trade and supply chains may lead to delays in the production and distribution of ALS medications and therapies. Increased regulatory scrutiny and trade restrictions can affect the availability of essential drugs and medical devices. Additionally, funding for ALS research may be diverted to address immediate geopolitical concerns, slowing advancements in treatment options. Fluctuations in currency exchange rates and economic instability can increase costs for healthcare providers and patients. Overall, geopolitical instability can hinder the accessibility and development of effective ALS treatments, impacting patient care and market growth.

Specialty Centers Are Major End Users of ALS Therapies

Global Amyotrophic Lateral Sclerosis (ALS) Market is comprised of specialty centers and research & academic institutes as end users. The specialty centers segment is a higher contributor to the growth of Global Amyotrophic Lateral Sclerosis (ALS) Market by end user. The segment dominates due to the specialized care and advanced treatment options provided by these centers, which cater specifically to ALS patients. These facilities offer comprehensive services, including diagnostics, multidisciplinary care, and access to clinical trials, making them the preferred choice for patients and driving their prominence in the market.

Competitive Landscape

Global Amayotrophic Lateral Sclerosis (ALS) Market is fiercely competitive, with numerous companies vying for a larger market share. Major companies in the market include Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd, BrainStorm Therapeutics, Biogen Inc., Corestem, AB Science, F. Hoffmann-La Roche AG, Biohaven Pharmaceutical, Sun Pharmaceutical, and Ionis Pharmaceuticals, Inc. These companies use various strategies, including increasing investments in their R&D activities, mergers and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in Global Amayotrophic Lateral Sclerosis (ALS) Market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Amayotrophic Lateral Sclerosis (ALS) Market. It also highlights the factors driving forecasts of total Market size. The report promises to provide recent technology trends in Global Amayotrophic Lateral Sclerosis (ALS) Market and industry insights to help decision-makers make sound strategic decisions. Further, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentation

2. Executive Summary

3. Global Amyotrophic Lateral Sclerosis (ALS) Market Insights

• 3.1. Industry Value Chain Analysis
• 3.2. DROC Analysis
  • 3.2.1. Growth Drivers
    • 3.2.1.1. Increasing prevalence of ALS globally
    • 3.2.1.2. Advances in medical research and technology for ALS treatment
    • 3.2.1.3. Growing healthcare expenditure and awareness
    • 3.2.1.4. Rising geriatric population susceptible to neurological disorders
  • 3.2.2. Restraints
    • 3.2.2.1. High cost of ALS treatment options
    • 3.2.2.2. Limited effectiveness of current therapies
    • 3.2.2.3. Stringent regulatory requirements for drug approval
  • 3.2.3. Opportunities
    • 3.2.3.1. Research and development initiatives for novel therapies
    • 3.2.3.2. Collaborations between pharmaceutical companies and research institutions
    • 3.2.3.3. Technological advancements in diagnostic tools for early detection
  • 3.2.4. Challenges
    • 3.2.4.1. Ethical concerns related to experimental ALS therapies
    • 3.2.4.2. Uneven access to ALS treatments across different regions
• 3.3. Technological Advancements/Recent Developments
• 3.4. Regulatory Framework
• 3.5. Porter's Five Forces Analysis
  • 3.5.1. Bargaining Power of Suppliers
  • 3.5.2. Bargaining Power of Buyers
  • 3.5.3. Threat of New Entrants
  • 3.5.4. Threat of Substitutes
  • 3.5.5. Intensity of Rivalry

4. Global Amyotrophic Lateral Sclerosis (ALS) Market: Marketing Strategies

5. Global Amyotrophic Lateral Sclerosis (ALS) Market: Pricing Analysis

6. Global Amyotrophic Lateral Sclerosis (ALS) Market: Geographical Analysis

7. Global Amyotrophic Lateral Sclerosis (ALS) Market Overview

• 7.1. Market Size & Forecast, 2019-2030
  • 7.1.1. By Value (USD Billion)
• 7.2. Market Share and Forecast
  • 7.2.1. By Type
    • 7.2.1.1. Sporadic ALS (SALS)
    • 7.2.1.2. Familial ALS (FALS)
  • 7.2.2. By Treatment
    • 7.2.2.1. Medication
    • 7.2.2.2. Physical Therapy
    • 7.2.2.3. Respiratory Therapy
    • 7.2.2.4. Speech Therapy
    • 7.2.2.5. Others
  • 7.2.3. By End User
    • 7.2.3.1. Specialty Centers
    • 7.2.3.2. Research & Academic Institutes
    • 7.2.3.3. Others
  • 7.2.4. By Region
    • 7.2.4.1. North America
    • 7.2.4.2. Europe
    • 7.2.4.3. Asia Pacific (APAC)
    • 7.2.4.4. Latin America (LATAM)
    • 7.2.4.5. Middle East and Africa (MEA)

8. North America Amyotrophic Lateral Sclerosis (ALS) Market

• 8.1. Market Size & Forecast, 2019-2030
  • 8.1.1. By Value (USD Billion)
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By End User
  • 8.2.4. By Country
    • 8.2.4.1. United States
    • 8.2.4.1.1. By Type
    • 8.2.4.1.2. By Treatment
    • 8.2.4.1.3. By End User
    • 8.2.4.2. Canada
    • 8.2.4.2.1. By Type
    • 8.2.4.2.2. By Treatment
    • 8.2.4.2.3. By End User

9. Europe Amyotrophic Lateral Sclerosis (ALS) Market

• 9.1. Market Size & Forecast, 2019-2030
  • 9.1.1. By Value (USD Billion)
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By End User
  • 9.2.4. By Country
    • 9.2.4.1. Germany
    • 9.2.4.1.1. By Type
    • 9.2.4.1.2. By Treatment
    • 9.2.4.1.3. By End User
    • 9.2.4.2. United Kingdom
    • 9.2.4.2.1. By Type
    • 9.2.4.2.2. By Treatment
    • 9.2.4.2.3. By End User
    • 9.2.4.3. Italy
    • 9.2.4.3.1. By Type
    • 9.2.4.3.2. By Treatment
    • 9.2.4.3.3. By End User
    • 9.2.4.4. France
    • 9.2.4.4.1. By Type
    • 9.2.4.4.2. By Treatment
    • 9.2.4.4.3. By End User
    • 9.2.4.5. Spain
    • 9.2.4.5.1. By Type
    • 9.2.4.5.2. By Treatment
    • 9.2.4.5.3. By End User
    • 9.2.4.6. Belgium
    • 9.2.4.6.1. By Type
    • 9.2.4.6.2. By Treatment
    • 9.2.4.6.3. By End User
    • 9.2.4.7. Russia
    • 9.2.4.7.1. By Type
    • 9.2.4.7.2. By Treatment
    • 9.2.4.7.3. By End User
    • 9.2.4.8. The Netherlands
    • 9.2.4.8.1. By Type
    • 9.2.4.8.2. By Treatment
    • 9.2.4.8.3. By End User
    • 9.2.4.9. Rest of Europe
    • 9.2.4.9.1. By Type
    • 9.2.4.9.2. By Treatment
    • 9.2.4.9.3. By End User

10. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market

• 10.1. Market Size & Forecast, 2019-2030
  • 10.1.1. By Value (USD Billion)
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment
  • 10.2.3. By End User
  • 10.2.4. By Country
    • 10.2.4.1. China
    • 10.2.4.1.1. By Type
    • 10.2.4.1.2. By Treatment
    • 10.2.4.1.3. By End User
    • 10.2.4.2. India
    • 10.2.4.2.1. By Type
    • 10.2.4.2.2. By Treatment
    • 10.2.4.2.3. By End User
    • 10.2.4.3. Japan
    • 10.2.4.3.1. By Type
    • 10.2.4.3.2. By Treatment
    • 10.2.4.3.3. By End User
    • 10.2.4.4. South Korea
    • 10.2.4.4.1. By Type
    • 10.2.4.4.2. By Treatment
    • 10.2.4.4.3. By End User
    • 10.2.4.5. Australia & New Zealand
    • 10.2.4.5.1. By Type
    • 10.2.4.5.2. By Treatment
    • 10.2.4.5.3. By End User
    • 10.2.4.6. Indonesia
    • 10.2.4.6.1. By Type
    • 10.2.4.6.2. By Treatment
    • 10.2.4.6.3. By End User
    • 10.2.4.7. Malaysia
    • 10.2.4.7.1. By Type
    • 10.2.4.7.2. By Treatment
    • 10.2.4.7.3. By End User
    • 10.2.4.8. Singapore
    • 10.2.4.8.1. By Type
    • 10.2.4.8.2. By Treatment
    • 10.2.4.8.3. By End User
    • 10.2.4.9. Vietnam
    • 10.2.4.9.1. By Type
    • 10.2.4.9.2. By Treatment
    • 10.2.4.9.3. By End User
    • 10.2.4.10. Rest of APAC
    • 10.2.4.10.1. By Type
    • 10.2.4.10.2. By Treatment
    • 10.2.4.10.3. By End User

11. Latin America Amyotrophic Lateral Sclerosis (ALS) Market

• 11.1. Market Size & Forecast, 2019-2030
  • 11.1.1. By Value (USD Billion)
• 11.2. Market Share & Forecast
  • 11.2.1. By Type
  • 11.2.2. By Treatment
  • 11.2.3. By End User
  • 11.2.4. By Country
    • 11.2.4.1. Brazil
    • 11.2.4.1.1. By Type
    • 11.2.4.1.2. By Treatment
    • 11.2.4.1.3. By End User
    • 11.2.4.2. Mexico
    • 11.2.4.2.1. By Type
    • 11.2.4.2.2. By Treatment
    • 11.2.4.2.3. By End User
    • 11.2.4.3. Argentina
    • 11.2.4.3.1. By Type
    • 11.2.4.3.2. By Treatment
    • 11.2.4.3.3. By End User
    • 11.2.4.4. Peru
    • 11.2.4.4.1. By Type
    • 11.2.4.4.2. By Treatment
    • 11.2.4.4.3. By End User
    • 11.2.4.5. Rest of LATAM
    • 11.2.4.5.1. By Type
    • 11.2.4.5.2. By Treatment
    • 11.2.4.5.3. By End User

12. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Market

• 12.1. Market Size & Forecast, 2019-2030
  • 12.1.1. By Value (USD Billion)
• 12.2. Market Share & Forecast
  • 12.2.1. By Type
  • 12.2.2. By Treatment
  • 12.2.3. By End User
  • 12.2.4. By Country
    • 12.2.4.1. Saudi Arabia
    • 12.2.4.1.1. By Type
    • 12.2.4.1.2. By Treatment
    • 12.2.4.1.3. By End User
    • 12.2.4.2. UAE
    • 12.2.4.2.1. By Type
    • 12.2.4.2.2. By Treatment
    • 12.2.4.2.3. By End User
    • 12.2.4.3. Qatar
    • 12.2.4.3.1. By Type
    • 12.2.4.3.2. By Treatment
    • 12.2.4.3.3. By End User
    • 12.2.4.4. Kuwait
    • 12.2.4.4.1. By Type
    • 12.2.4.4.2. By Treatment
    • 12.2.4.4.3. By End User
    • 12.2.4.5. South Africa
    • 12.2.4.5.1. By Type
    • 12.2.4.5.2. By Treatment
    • 12.2.4.5.3. By End User
    • 12.2.4.6. Nigeria
    • 12.2.4.6.1. By Type
    • 12.2.4.6.2. By Treatment
    • 12.2.4.6.3. By End User
    • 12.2.4.7. Algeria
    • 12.2.4.7.1. By Type
    • 12.2.4.7.2. By Treatment
    • 12.2.4.7.3. By End User
    • 12.2.4.8. Rest of MEA
    • 12.2.4.8.1. By Type
    • 12.2.4.8.2. By Treatment
    • 12.2.4.8.3. By End User

13. Competitive Landscape

• 13.1. List of Key Players and Their Offerings
• 13.2. Global Amyotrophic Lateral Sclerosis (ALS) Market Share Analysis, 2023
• 13.3. Competitive Benchmarking, By Operating Parameters
• 13.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

14. Impact of Escalating Geopolitical Tensions on Global Amyotrophic Lateral Sclerosis (ALS) Market

15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

• 15.1. Mitsubishi Tanabe Pharma Corporation
• 15.2. Otsuka Pharmaceutical Co., Ltd
• 15.3. BrainStorm Therapeutics
• 15.4. Biogen Inc.
• 15.5. Corestem
• 15.6. AB Science
• 15.7. F.Hoffmann-La Roche AG
• 15.8. Biohaven Pharmaceutical
• 15.9. Sun Pharmaceutical
• 15.10. Ionis Pharmaceuticals, Inc.
• 15.11. Other Prominent Players

16. Key Strategic Recommendations

17. Research Methodology

• 17.1. Qualitative Research
  • 17.1.1. Primary & Secondary Research
• 17.2. Quantitative Research
• 17.3. Market Breakdown & Data Triangulation
  • 17.3.1. Secondary Research
  • 17.3.2. Primary Research
• 17.4. Breakdown of Primary Research Respondents, By Region
• 17.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable